Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVJF) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Teva Pharmaceutical Industries (TEVJF) over the last 17 years, with Q4 2025 value amounting to $1.4 billion.

  • Teva Pharmaceutical Industries' Net Cash Flow rose 122330.1% to $1.4 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $235.0 million, marking a year-over-year decrease of 524.19%. This contributed to the annual value of $235.0 million for FY2025, which is 524.19% down from last year.
  • As of Q4 2025, Teva Pharmaceutical Industries' Net Cash Flow stood at $1.4 billion, which was up 122330.1% from $51.0 million recorded in Q3 2025.
  • Teva Pharmaceutical Industries' 5-year Net Cash Flow high stood at $1.4 billion for Q4 2025, and its period low was -$1.6 billion during Q1 2025.
  • Its 5-year average for Net Cash Flow is $90.7 million, with a median of $108.5 million in 2022.
  • As far as peak fluctuations go, Teva Pharmaceutical Industries' Net Cash Flow soared by 168611.11% in 2023, and later plummeted by 115801.53% in 2025.
  • Over the past 5 years, Teva Pharmaceutical Industries' Net Cash Flow (Quarter) stood at $201.0 million in 2021, then skyrocketed by 113.93% to $430.0 million in 2022, then skyrocketed by 111.4% to $909.0 million in 2023, then plummeted by 88.67% to $103.0 million in 2024, then skyrocketed by 1223.3% to $1.4 billion in 2025.
  • Its Net Cash Flow stands at $1.4 billion for Q4 2025, versus $51.0 million for Q3 2025 and $469.0 million for Q2 2025.